ERBB2 and breast cancer: PIK3CA mutations and, in general, alterations in the PI3K/AKT pathway, play a major role in the biology of BC, which is better established in the HR+/HER2- BC subtype than in TNBC and HER2+ BC for which research efforts are still needed.